Literature DB >> 32213034

Albumin: Indications in chronic liver disease.

Manuel Tufoni1, Giacomo Zaccherini1, Paolo Caraceni1, Mauro Bernardi1.   

Abstract

Albumin is currently employed as a plasma expander to prevent and treat specific complications of cirrhosis with ascites, such as the prevention of paracentesis-induced circulatory dysfunction and renal dysfunction induced by spontaneous bacterial peritonitis, as well as the diagnosis and treatment of acute kidney injury and hepatorenal syndrome. Recently, evidence has shown that long-term albumin administration in patients with decompensated cirrhosis reduces mortality and incidence of complications, eases the management of ascites, is cost effective, and has a good safety profile.

Entities:  

Keywords:  Liver cirrhosis; acute kidney injury; ascites; hepatorenal syndrome; human albumin; paracentesis; spontaneous bacterial peritonitis

Mesh:

Substances:

Year:  2020        PMID: 32213034      PMCID: PMC7268936          DOI: 10.1177/2050640620910339

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN: 2050-6406            Impact factor:   4.623


  40 in total

1.  Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial.

Authors:  Elsa Solà; Cristina Solé; Macarena Simón-Talero; Marta Martín-Llahí; José Castellote; Rita Garcia-Martínez; Rebeca Moreira; Maria Torrens; Francisca Márquez; Núria Fabrellas; Gloria de Prada; Patrícia Huelin; Eva Lopez Benaiges; Meritxell Ventura; Marcela Manríquez; André Nazar; Xavier Ariza; Pilar Suñé; Isabel Graupera; Elisa Pose; Jordi Colmenero; Marco Pavesi; Mónica Guevara; Miquel Navasa; Xavier Xiol; Joan Córdoba; Victor Vargas; Pere Ginès
Journal:  J Hepatol       Date:  2018-08-21       Impact factor: 25.083

2.  EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis.

Authors: 
Journal:  J Hepatol       Date:  2018-04-10       Impact factor: 25.083

3.  Randomized controlled trial comparing lactulose plus albumin versus lactulose alone for treatment of hepatic encephalopathy.

Authors:  Barjesh Chander Sharma; Jatinderpal Singh; Siddharth Srivastava; Alok Sangam; Alok Kumar Mantri; Nirupma Trehanpati; Shiv Kumar Sarin
Journal:  J Gastroenterol Hepatol       Date:  2017-06       Impact factor: 4.029

Review 4.  Non-oncotic properties of albumin. A multidisciplinary vision about the implications for critically ill patients.

Authors:  Ricard Ferrer; Xavier Mateu; Emilio Maseda; Juan Carlos Yébenes; César Aldecoa; Candelaria De Haro; Juan Carlos Ruiz-Rodriguez; José Garnacho-Montero
Journal:  Expert Rev Clin Pharmacol       Date:  2017-12-08       Impact factor: 5.045

5.  A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis.

Authors:  Javier Fernández; Joan Monteagudo; Xavier Bargallo; Wladimiro Jiménez; Jaume Bosch; Vicente Arroyo; Miguel Navasa
Journal:  Hepatology       Date:  2005-09       Impact factor: 17.425

Review 6.  The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club.

Authors:  Kevin P Moore; Florence Wong; Pere Gines; Mauro Bernardi; Andreas Ochs; Francesco Salerno; Paolo Angeli; Michael Porayko; Richard Moreau; Guadelupe Garcia-Tsao; Wladimiro Jimenez; Ramon Planas; Vicente Arroyo
Journal:  Hepatology       Date:  2003-07       Impact factor: 17.425

7.  Oxidized Albumin Triggers a Cytokine Storm in Leukocytes Through P38 Mitogen-Activated Protein Kinase: Role in Systemic Inflammation in Decompensated Cirrhosis.

Authors:  José Alcaraz-Quiles; Mireia Casulleras; Karl Oettl; Esther Titos; Roger Flores-Costa; Marta Duran-Güell; Cristina López-Vicario; Marco Pavesi; Rudolf E Stauber; Vicente Arroyo; Joan Clària
Journal:  Hepatology       Date:  2018-10-13       Impact factor: 17.425

8.  Reversal of diuretic-induced hepatic encephalopathy with infusion of albumin but not colloid.

Authors:  Rajiv Jalan; Dharmesh Kapoor
Journal:  Clin Sci (Lond)       Date:  2004-05       Impact factor: 6.124

9.  Positive cardiac inotropic effect of albumin infusion in rodents with cirrhosis and ascites: molecular mechanisms.

Authors:  Alessia Bortoluzzi; Giulio Ceolotto; Elisabetta Gola; Antonietta Sticca; Sergio Bova; Filippo Morando; Salvatore Piano; Silvano Fasolato; Silvia Rosi; Angelo Gatta; Paolo Angeli
Journal:  Hepatology       Date:  2013-01       Impact factor: 17.425

10.  Albumin infusion may decrease the incidence and severity of overt hepatic encephalopathy in liver cirrhosis.

Authors:  Zhaohui Bai; Mauro Bernardi; Eric M Yoshida; Hongyu Li; Xiaozhong Guo; Nahum Méndez-Sánchez; Yingying Li; Ran Wang; Jiao Deng; Xingshun Qi
Journal:  Aging (Albany NY)       Date:  2019-10-08       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.